| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00927563 | Pathological Gambling | Drug: Tolcapone | University of Chicago | Phase 2 | 2009-06-01 | 2014-01-17 |
| NCT02630043 | Neuroblastoma | Drug: Tolcapone|Drug: Oxaliplatin | Spectrum Health Hospitals | Phase 1 | 2015-12-01 | 2016-09-14 |
| NCT02740582 | Alcohol Abuse|Impulsive Behavior | Drug: Tolcapone|Drug: Placebo | University of California, San Francisco | | 2016-10-01 | 2017-01-12 |
| NCT01202955 | Nicotine Dependence | Drug: Tolcapone|Drug: Placebo | University of Pennsylvania | Phase 2 | 2008-07-01 | 2011-05-04 |
| NCT02652598 | Brain Injuries, Traumatic|Neurocognitive Disorders|Brain Injuries | Drug: Tolcapone | Sheppard Pratt Health System|Lieber Institute for Brain Development (LIBD) | Phase 2 | 2015-11-01 | 2017-01-17 |
| NCT02080715 | Healthy | Drug: Tolcapone|Drug: Placebo | University of Zurich | Phase 1 | 2013-06-01 | 2014-09-11 |
| NCT00604591 | Frontotemporal Lobar Degeneration | Drug: Tolcapone|Drug: Placebo | Columbia University|National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2011-07-01 | 2016-06-14 |
| NCT00044083 | Schizophrenia | Drug: Tolcapone | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2002-08-01 | 2016-08-31 |
| NCT00033059 | Cocaine-Related Disorders | Drug: Tolcapone | National Institute on Drug Abuse (NIDA) | Phase 1 | 2001-07-01 | 2017-01-10 |
| NCT02448654 | Nicotine Dependence | Drug: Tolcapone|Drug: Sugar Pill | Yale University|VA Office of Research and Development | | 2015-10-01 | 2016-07-18 |
| NCT02191826 | Familial Amyloid Polyneuropathy (FAP) | Drug: SOM0226 | SOM Biotech SL|Hospital Vall d'Hebron | Phase 1|Phase 2 | 2014-07-01 | 2016-11-29 |
| NCT02949934 | Alcohol Use Disorder | Drug: Tolcapone|Drug: Placebo | Medical University of South Carolina|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2016-05-01 | 2016-10-27 |
| NCT01001520 | Tobacco Use Disorder | Drug: Tolcapone|Drug: Placebo | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Phase 2 | 2010-01-01 | 2014-05-29 |
| NCT02929485 | Addiction | Drug: Tolcapone|Drug: Placebo|Drug: Bromocriptine | University of California, San Francisco|University of California, Berkeley | | 2013-07-01 | 2016-10-10 |
| NCT02772978 | Pathological Gambling | Drug: Tolcapone|Drug: Placebo | University of California, San Francisco|National Center for Responsible Gaming | | 2014-08-01 | 2016-05-12 |
| NCT02260570 | Mild Traumatic Brain Injury | Drug: Tolcapone|Drug: Placebo | VA Office of Research and Development|University of California, Berkeley|University of California, San Francisco | 2015-08-01 | 2017-03-13 |
| NCT01158950 | Impulsive Behavior | Drug: Tolcapone|Other: Placebo|Drug: Entacapone | University of California, San Francisco|University of California, Berkeley|United States Department of Defense | 2010-03-01 | 2016-04-12 |
| NCT00906828 | Parkinson Disease | Drug: levodopa/carbidopa|Drug: entacapone|Drug: tolcapone | Uppsala University|Swedish Parkinson's Disease Foundation|Swedish Society for Medical Research | Phase 4 | 2008-10-01 | 2010-01-15 |
| NCT02994719 | Parkinson's Disease|Parkinsonian Disorders|Atypical Parkinson Disease|Progressive Supranuclear Palsy|Multiple System Atrophy|Corticobasal Degeneration|Gait, Frontal | Drug: Anti-Parkinson medication|Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | | 2016-03-01 | 2017-03-09 |
